| pubmed-article:2520621 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2520621 | lifeskim:mentions | umls-concept:C0677659 | lld:lifeskim |
| pubmed-article:2520621 | lifeskim:mentions | umls-concept:C0014869 | lld:lifeskim |
| pubmed-article:2520621 | lifeskim:mentions | umls-concept:C0034665 | lld:lifeskim |
| pubmed-article:2520621 | lifeskim:mentions | umls-concept:C0520010 | lld:lifeskim |
| pubmed-article:2520621 | lifeskim:mentions | umls-concept:C0206012 | lld:lifeskim |
| pubmed-article:2520621 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2520621 | pubmed:dateCreated | 1992-6-15 | lld:pubmed |
| pubmed-article:2520621 | pubmed:abstractText | H2-receptor antagonists administered in conventional dosage regimens fail to heal a significant proportion of patients with moderate or severe reflux oesophagitis. We have compared the effects of a higher dose of ranitidine (300 mg q.d.s.) with the currently recommended dosage regimen (150 mg b.d.) in 138 patients suffering from reflux oesophagitis. After 4 weeks of treatment 29% of patients who received 150 mg ranitidine b.d., and 63% of patients who received 300 mg ranitidine q.d.s. had complete endoscopic healing of their lesions (P less than 0.0001). After 8 weeks these proportions had increased to 54% and 75%, respectively (P less than 0.01). After 4 weeks of treatment, compete symptomatic relief had been achieved in 46% of patients who received 150 mg ranitidine b.d. and in 67% of patients who received 300 mg ranitidine q.d.s. (P less than 0.05). After 8 weeks these proportions were 64% and 84%, respectively (P less than 0.05). Both dosage schedules were well-tolerated. We conclude that more rapid symptom relief and healing in reflux oesophagitis can be achieved with 300 mg ranitidine q.d.s. than with 150 mg ranitidine b.d. | lld:pubmed |
| pubmed-article:2520621 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2520621 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520621 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2520621 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2520621 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2520621 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:2520621 | pubmed:issn | 0269-2813 | lld:pubmed |
| pubmed-article:2520621 | pubmed:author | pubmed-author:MillsJ GJG | lld:pubmed |
| pubmed-article:2520621 | pubmed:author | pubmed-author:WoodJ RJR | lld:pubmed |
| pubmed-article:2520621 | pubmed:author | pubmed-author:JohnsonN JNJ | lld:pubmed |
| pubmed-article:2520621 | pubmed:author | pubmed-author:BoydE JEJ | lld:pubmed |
| pubmed-article:2520621 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2520621 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:2520621 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2520621 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2520621 | pubmed:pagination | 259-66 | lld:pubmed |
| pubmed-article:2520621 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:meshHeading | pubmed-meshheading:2520621-... | lld:pubmed |
| pubmed-article:2520621 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2520621 | pubmed:articleTitle | Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. | lld:pubmed |
| pubmed-article:2520621 | pubmed:affiliation | Department of Gastroenterology, Glaxo Group Research Ltd, Greenford, Middlesex, UK. | lld:pubmed |
| pubmed-article:2520621 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2520621 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2520621 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2520621 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2520621 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2520621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2520621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2520621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2520621 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2520621 | lld:pubmed |
